Lab trial product, 4-Hydroxymethyl-5-methyl-2-phenylimidazole, qualified for EMC curing accelerator

Our lab trial product, 4-Hydroxymethyl-5-methyl-2-phenylimidazole, has been qualified by testing at the customer side for her EMC formula development. This new product is a thermally latent catalyst with specific characteristics to control EMC curing rate at the designed molding condition. In the EMC curing process, the catalyst with different particle size or different crystal structure significantly impacts curing performance. Smaller particles have bigger surface area to promote cross-linking reaction for faster curing rate while larger particles might cause delayed melting and abnormal appearances during processing. However, powder with fine particles with lower flowability is the challenge to have uneven mixing with the other components, which should be considered in the formula design to secure the consistency of curing performance. By following the customer request, we keep same rhythm with the customer R&D team in the EMC formula development project to make intensive trials in the laboratory for optimizing synthesis parameters and improving crystallization process. Recently, we got the customer feedback that our samples had been tested and presented good performance on crystal structure, particle size & distribution, DSC, and TGA. The lab trial will guide to scale up for production campaign to trial for intra-batch and inter-batch qualification with consistent quality.